


TITLE: Adenosine A3 antagonists  
 INVENTOR(S): Sugiura, Yoshihiro; Miwatari, Seiji; Kimura, Hiroyuki; Knzaki, Naoyuki  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11158073	A	19990615	JP 1998-270755	19980925 <--
PRIORITY APPLN. INFO.:			JP 1997-262525	A 19970926 <--
OTHER SOURCE(S): MARPAT 131:78466				
ED Entered STN: 23 Jun 1999				
GI				




AB Adenosine A3 receptor antagonists contain (un)substituted amino-substituted N2-3-containing heterocyclic [5-8 ring-containing] compds. such as 2-chloro-4-ethylamino-6-phenylamino-1,3,5-triazine and 2,4-bis[phenylamino]-6-cyclohexylamino-1,3,5-triazine. Of 6 compds. tested, the IC50 values of adenosine A3 receptor antagonist activities ranged from 0.7 to 285.9 nM as determined in human adenosine A3 receptor-expressing plasmid-transformed CHO (dhfr-) cell cultures. Tablets were formulated containing 2,4-bis[phenylamino]-6-cyclohexylamino- 1,3,5-triazine 50, lactose 34, corn starch 10.6, corn starch paste 5, magnesium stearate 0.4 and calcium CM-cellulose 20 mg. The drugs are useful for treating e.g. brain ischemic disease.

IT 228575-19-7 228575-20-0 228575-21-1  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (adenosine A3 receptor antagonists and pharmaceutical compns.)

IT 228575-19-7 228575-20-0 228575-21-1  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (adenosine A3 receptor antagonists and pharmaceutical compns.)


RN 228575-19-7 HCAPLUS  
 CN Pyrimidine, 4-hydrazinyl-6-phenoxy-2-phenyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 228575-20-0 HCAPLUS

CN 4-Pyrimidinamine, 6-phenoxy-N,2-diphenyl- (CA INDEX NAME)



RN 228575-21-1 HCAPLUS

CN 4-Pyrimidinamine, N-cyclohexyl-6-phenoxy-2-phenyl-, hydrochloride (1:1)  
(CA INDEX NAME)




● HCl

OS.CITING REF COUNT: 7


THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD  
(7 CITINGS)

=> d stat query L11  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 44253 SEA FILE=REGISTRY SSS FUL L1  
L4 STR



G1:O,S

Structure attributes must be viewed using STN Express query preparation.

L6 645 SEA FILE=REGISTRY SUB=L3 SSS FUL L4  
L7 76 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L6  
L8 35 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L7 AND (THU/RL OR  
DGN/RL OR DMA/RL OR PAC/RL OR PKT/RL OR ADV/RL)  
L9 17 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L8 AND (AY<2007 OR  
PY<2007 OR PRY<2007 OR REVIEW/DT)  
L11 18 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L8 NOT L9